Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017 [Corrigendum]

Abstract

Mahboub BH, Vats MG, Al Zaabi A, Iqbal MN, Safwat T, Al-Hurish F, Miravitlles M, Singh D, Asad K, Zeineldine S, Al-Hajjaj MS. Int J Chron Obstruct Pulmon Dis. 2017;12: 2869–2890. Page 2885, Disclosure, the text “The authors report no conflicts of interest in this work” should read “BHM has a pending patent for Samsum sublingual immunotherapy with the US Patent and Trademark Office. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. DS has received speaking/consultancy fees from Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, Glenmark, Merck, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skyepharma, Therevance and Verona; and research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Therevance and Verona. The authors report no other conflicts of interest in this work”.